INT7258

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 1988
Last Reported 2009
Negated 0
Speculated 1
Reported most in Abstract
Documents 42
Total Number 45
Disease Relevance 0.17
Pain Relevance 17.85

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Sult1b1) cytoplasm (Sult1b1)
Anatomy Link Frequency
striatum 5
astrocytes 2
brain 1
nucleus 1
cortex 1
Sult1b1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Dopamine 130 100.00 Very High Very High Very High
Glutamate 16 100.00 Very High Very High Very High
Nicotine 79 99.98 Very High Very High Very High
agonist 18 99.64 Very High Very High Very High
GABAergic 6 99.54 Very High Very High Very High
Clonidine 3 99.32 Very High Very High Very High
gABA 42 99.30 Very High Very High Very High
tolerance 3 99.28 Very High Very High Very High
tetrodotoxin 36 99.08 Very High Very High Very High
withdrawal 15 98.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Death 2 90.12 High High
Disease 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The turnover rate of DOPA was about 300 times higher compared to DA. (+/-)-Nicotine (10 microM)-induced DOPA release was mecamylamine (20 microM)-sensitive, Ca2(+)-dependent and tetrodotoxin (0.3 microM)-insensitive.
Localization (release) of DOPA associated with tetrodotoxin, dopamine and nicotine
1) Confidence 0.68 Published 1990 Journal Brain Res. Section Abstract Doc Link 2119849 Disease Relevance 0 Pain Relevance 0.65
The (+/-)-nicotine (200 microM)-induced DOPA release was mecamylamine (500 microM)-sensitive, tetrodotoxin (100 nM)-sensitive and Ca2+ (removal plus 12.5 mM Mg2+ addition)-dependent.
Localization (release) of DOPA associated with tetrodotoxin and nicotine
2) Confidence 0.68 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361443 Disease Relevance 0 Pain Relevance 0.64
Nicotine was perfused for 20 min through a probe. (+/-)-Nicotine (100-300 microM) constantly and repeatedly released DOPA and DA over a similar time course in a dose-dependent manner.
Localization (released) of DOPA associated with dopamine and nicotine
3) Confidence 0.60 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361443 Disease Relevance 0 Pain Relevance 0.59
Microdialysis and high performance liquid chromatography with an electrochemical detector were applied to compare the characteristics of nicotine-evoked release of endogenous 3,4-dihydroxyphenylalanine (DOPA) from striata of conscious rats and those of the release of dopamine (DA).
Localization (release) of DOPA associated with dopamine and nicotine
4) Confidence 0.60 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361443 Disease Relevance 0 Pain Relevance 0.44
The (+)-isomer produced no DOPA release.
Localization (release) of DOPA
5) Confidence 0.60 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361443 Disease Relevance 0 Pain Relevance 0.64
Furthermore, mecamylamine alone inhibited the basal release of DOPA but not of DA.
Localization (release) of DOPA associated with dopamine
6) Confidence 0.60 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361443 Disease Relevance 0 Pain Relevance 0.63
The (+)-isomer induced no DOPA release.
Localization (release) of DOPA
7) Confidence 0.60 Published 1990 Journal Brain Res. Section Abstract Doc Link 2119849 Disease Relevance 0 Pain Relevance 0.65
In superfused slices of rat striatum, nicotine-evoked release of endogenous 3,4-dihydroxyphenylalanine (DOPA) was studied in comparison with that of dopamine (DA). (+/-)-Nicotine (0.1-10 microM) constantly and repetitively released DOPA and DA over a similar time course in a concentration-dependent manner.
Localization (release) of DOPA in striatum associated with dopamine and nicotine
8) Confidence 0.60 Published 1990 Journal Brain Res. Section Abstract Doc Link 2119849 Disease Relevance 0 Pain Relevance 0.51
In superfused slices of rat striatum, nicotine-evoked release of endogenous 3,4-dihydroxyphenylalanine (DOPA) was studied in comparison with that of dopamine (DA). (+/-)-Nicotine (0.1-10 microM) constantly and repetitively released DOPA and DA over a similar time course in a concentration-dependent manner.
Localization (released) of DOPA in striatum associated with dopamine and nicotine
9) Confidence 0.60 Published 1990 Journal Brain Res. Section Abstract Doc Link 2119849 Disease Relevance 0 Pain Relevance 0.58
These characteristics of DOPA release were almost the same as those of DA.
Localization (release) of DOPA associated with dopamine
10) Confidence 0.60 Published 1990 Journal Brain Res. Section Abstract Doc Link 2119849 Disease Relevance 0 Pain Relevance 0.65
These characteristics of DOPA release were almost the same as those of DA release.
Localization (release) of DOPA associated with dopamine
11) Confidence 0.60 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361443 Disease Relevance 0 Pain Relevance 0.64
The ratio of the DOPA and DA release evoked was approximately 1:3.
Localization (release) of DOPA associated with dopamine
12) Confidence 0.60 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361443 Disease Relevance 0 Pain Relevance 0.63
These acetylcholine receptors function tonically for the release of DOPA.
Localization (release) of DOPA
13) Confidence 0.60 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361443 Disease Relevance 0 Pain Relevance 0.57
Nicotine released stereoselectively endogenous DOPA via nicotinic acetylcholine receptors from striata of freely moving rats in a manner similar to transmitter DA.
Localization (released) of DOPA associated with dopamine and nicotine
14) Confidence 0.60 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361443 Disease Relevance 0 Pain Relevance 0.62
These findings suggest that striatal DOPA is released by a Ca2+-dependent excitation-secretion coupling process similar to that involved in transmitter release.
Localization (secretion) of DOPA
15) Confidence 0.32 Published 1988 Journal J. Neurochem. Section Abstract Doc Link 2897424 Disease Relevance 0 Pain Relevance 0.12
Characteristics of the DOPA release were compared with those of 3,4-dihydroxyphenylethylamine (dopamine, DA).
Localization (release) of DOPA associated with dopamine
16) Confidence 0.32 Published 1988 Journal J. Neurochem. Section Abstract Doc Link 2897424 Disease Relevance 0 Pain Relevance 0.12
Electrical stimulation at 2 Hz evoked DOPA and DA over similar time courses. alpha-Methyl-p-tyrosine (0.2 mM) markedly reduced release of DOPA but not of DA.
Localization (release) of DOPA
17) Confidence 0.32 Published 1988 Journal J. Neurochem. Section Abstract Doc Link 2897424 Disease Relevance 0 Pain Relevance 0.14
These findings suggest that striatal DOPA is released by a Ca2+-dependent excitation-secretion coupling process similar to that involved in transmitter release.
Localization (released) of DOPA
18) Confidence 0.32 Published 1988 Journal J. Neurochem. Section Abstract Doc Link 2897424 Disease Relevance 0 Pain Relevance 0.12
The impulse-evoked release of DOPA and DA was completely tetrodotoxin (0.3 microM) sensitive and Ca2+ dependent and the 15 mM K+-evoked release was also Ca2+ dependent.
Localization (release) of DOPA associated with tetrodotoxin
19) Confidence 0.32 Published 1988 Journal J. Neurochem. Section Abstract Doc Link 2897424 Disease Relevance 0 Pain Relevance 0.14
Maximal release (0.3 pmol) of DOPA was obtained at 2 Hz and at 15 mM K+.
Localization (release) of DOPA
20) Confidence 0.32 Published 1988 Journal J. Neurochem. Section Abstract Doc Link 2897424 Disease Relevance 0 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox